But, more concerning than the success or failure of a particular company, was this question: What would happen to 23andMe's vast trove of highly personal customer data? We aren't just talking about usernames and birthdays.

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news release. Regeneron’s purchase does not include 23andMe’s Lemonaid Health business.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.